No qualifying author-owned investment thesis was confirmed in this post.
The author explicitly states they have no position and asks the community for their read, rather than expressing their own directional investment judgment.
Score4
Comments10
▶ Full Post Text
Vance Frost | Clinical Ops Analyst | 20 yrs clinical
CEO controls \~90% of voting power via super-voting Class V shares. HIMS built a real cash-pay subscription platform. Then it stepped into the one lane where "scale first, compliance later" doesn't fly.
Two businesses, one ticker:
1. The boring one that works: hair/ED/derm/mental health subscriptions.
2. The risky one: mass-marketed compounded GLP-1s pushed through a national funnel.
Why the GLP-1 lane got ugly:
* Feb 21, 2025: FDA said the semaglutide injection shortage was resolved.
* Sep 2025: FDA warning letter (dba Hers): marketing implying compounded semaglutide was the same as FDA-approved product = false/misleading; misbranding language.
* Feb 2026: FDA/HHS signaled enforcement posture; Reuters reported HHS said it would refer the matter to DOJ (civil or criminal exposure possible).
* Feb 9, 2026: Novo Nordisk filed a patent suit (reported), seeking to stop sales and pursue damages.
Balance sheet reality: Liquidity \~$1.1B (as stated in shareholder letter). Convertible notes: \~$1.0B principal due 2030 (fair value \~$1.12B as of Sep 30, 2025 per 10-Q). If the stock stays far below conversion, that's just debt.
Bottom line: The platform is real. But if your growth engine lives inside the enforcement line around mass marketing non-approved compounded GLP-1s, that revenue is conditional. Not durable.
What's your read... is the non-GLP-1 business strong enough to carry HIMS through this, or does the regulatory/legal overhang poison the whole ticker?
Disclosure: No position in HIMS. Not investment advice. Not medical or legal advice. Sources: SEC filings, FDA publications, and Reuters reporting on related regulatory/legal actions.